The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
LL-37 · hCAP18-Derived Peptide · CAMP
Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.
Same compound, route-specific context. Switch forms instead of opening separate pages.
Use the route notes below to match form, goal, and evidence quality.
No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.
Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.
Human controlled evidence is topical/local chronic-wound LL-37 data such as venous leg ulcer and diabetic foot ulcer studies; systemic immune or injectable community use is not route-matched RCT evidence.
LL-37 is the only human cathelicidin — a 37-amino acid master coordinator of innate immunity, wound healing, and angiogenesis with genuine clinical trial evidence for topical wound healing and the most complex bidirectional cancer pharmacology of any compound in this reference.
The central tension resolved: LL-37's clinical evidence is real and concentrated in topical wound healing for LL-37-deficient chronic wounds — venous leg ulcers and diabetic foot ulcers. In that context, topical LL-37 is pharmacologically rational, evidence-supported, and well-tolerated. The 6-fold healing rate acceleration in the Grönberg 2014 VLU trial is a genuine and clinically meaningful result. No bacterial resistance development makes LL-37-based wound treatments particularly interesting for MRSA and multi-drug-resistant wound infections. The cancer paradox is the most critical safety issue and requires the most careful treatment: LL-37 is documented as pro-tumor in ovarian, breast, lung, melanoma, and prostate cancers through specific receptor-mediated mechanisms. Systemic injectable LL-37 for immune optimization distributes LL-37 to all tissues simultaneously, including potentially pre-malignant cells in cancer-relevant tissues, without the tissue-specific context control that physiological LL-37 production provides. The rosacea risk from excess LL-37 is real, mechanistically established, and can produce irreversible skin changes.
The practical guidance: the most evidence-supported, safest route to optimizing the cathelicidin arm of innate immunity is vitamin D optimization. Topical LL-37 for genuine LL-37-deficient chronic wound healing is the appropriate clinical application of the compound. Systemic injectable LL-37 for general immune optimization carries risks disproportionate to the evidence base supporting the use.
The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.
Adds KPV’s local gut anti-inflammatory signal to the GLOW recovery-and-skin stack.
Alpha-MSH's Anti-Inflammatory Fragment — And It May Work Completely Differently Than Everyone Thinks
Scope appropriateness is the question: local gut peptides are being stacked for barrier integrity and inflammatory signaling, not for systemic regeneration claims.